News
![Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 2, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
![Savara Obtains Global Rights to Develop and Commercialize Apulmiq](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Savara Obtains Global Rights to Develop and Commercialize Apulmiq
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the Company has entered into an exclusive license and collaboration agreement with Grifols for Apulmiq (inhaled liposomal
![Epigenomics: US-Investoren zeichnen Aktien – jetzt rein?](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Epigenomics: US-Investoren zeichnen Aktien – jetzt rein?
Epigenomics (WKN: A11QW5) nimmt frisches Kapital auf. Dazu werden Aktien zu einem Preis von je 1,11 Euro bei Investoren platziert. Heute kommt die Bestätigung, dass institutionelle Investoren aus
![Navidea Biopharmaceuticals Signs Letter of Intent with WorldCare Clinical to Partner on Navidea’s Rheumatoid Arthritis Clinical Imaging Workflow and Commercialization; Other Business Updates](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Navidea Biopharmaceuticals Signs Letter of Intent with WorldCare Clinical to Partner on Navidea’s Rheumatoid Arthritis Clinical Imaging Workflow and Commercialization; Other Business Updates
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
![Bionomics and MSD Scientists Publish Preclinical Findings for BNC375 in Peer-Reviewed Journal](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Bionomics and MSD Scientists Publish Preclinical Findings for BNC375 in Peer-Reviewed Journal
Bionomics Limited (ASX: BNO, OTCQB:BNOEF), a global, clinical stage biopharmaceutical company, today announced that a paper describing the pharmacology of BNC375, a novel positive allosteric
![IMV Inc. Announces Fourth Quarter and Full Year 2019 Financial and Operational Results](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
IMV Inc. Announces Fourth Quarter and Full Year 2019 Financial and Operational Results
IMV Inc. (the “Company” or “IMV”) (TSX:IMV; NASDAQ:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational
![Savara Provides Business Update in Response to COVID-19 Pandemic](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Savara Provides Business Update in Response to COVID-19 Pandemic
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided an update on the impact COVID-19 has had on two of the Company’s clinical studies in cystic fibrosis (CF). Due to the
![IMV Inc. Provides Updates on the Development of DPX-COVID-19 Vaccine and Ongoing Business and Clinical Operations](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
IMV Inc. Provides Updates on the Development of DPX-COVID-19 Vaccine and Ongoing Business and Clinical Operations
IMV Inc. (Nasdaq: IMV) (TSX: IMV), a clinical-stage biopharmaceutical company (the “Company” or “IMV”), today provided updates on the development of DPX-COVID-19, a vaccine candidate against the
![Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that in connection with the appointment of Jeff Ludwig as Puma’s Chief Commercial Officer, the Compensation Committee
![IMV to Announce Fourth Quarter and Full Year 2019 Financial and Operational Results and Host Investor Conference Call and Webcast on March 31, 2020](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
IMV to Announce Fourth Quarter and Full Year 2019 Financial and Operational Results and Host Investor Conference Call and Webcast on March 31, 2020
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, announced today that it will hold a conference
![Novavax: Nicht Corona, sondern Influenza!](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Novavax: Nicht Corona, sondern Influenza!
Die Aktie des kleinen Biotechunternehmens Novavax (WKN: A2PKMZ) gehörte in den letzten Wochen schon zu den größten Gewinnern an der Börse (wir berichteten).
Grund hierfür war, dass Novavax sich auf
![ADMA Biologics: NBCler feiern +127% mitten in der Krise](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
ADMA Biologics: NBCler feiern +127% mitten in der Krise
Erst letzte Woche konnten Mitglieder des No Brainer Clubs bei ADMA Biologics (WKN: A12FAG) die ersten +50% nach wenigen Stunden feiern und bereits am Freitag wurde unser offizielles Tradingziel von
![Navidea Biopharmaceuticals Announces Issuance of Patent Extension for Lymphoseek®](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Navidea Biopharmaceuticals Announces Issuance of Patent Extension for Lymphoseek®
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
![ADMA Biologics: Neue NBC-Granate mit +53% in wenigen Stunden!](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
ADMA Biologics: Neue NBC-Granate mit +53% in wenigen Stunden!
Aufmerksame Chat-Nutzer kannten die Aktie von ADMA Biologics (WKN: A12FAG) bereits. Der No Brainer Club nahm den Wert gestern in sein Portfolio auf und sprach eine Kaufempfehlung aus. Innerhalb
![IMV Inc. Establishes At-the-Market Facility](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
IMV Inc. Establishes At-the-Market Facility
IMV Inc. (TSX: IMV; NASDAQ: IMV) (the "Company" or “IMV”), a clinical-stage biopharmaceutical company, today announced that it has entered into an equity distribution agreement, dated March 18
![IMV Inc. Launches Plans to Advance Clinical Development of a Vaccine Candidate Against COVID-19](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
IMV Inc. Launches Plans to Advance Clinical Development of a Vaccine Candidate Against COVID-19
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company (the “Company” or “IMV”), today announced that it is advancing the clinical development of a DPX-based vaccine candidate
![Aurinia Announces AURORA Phase 3 Clinical Data for Voclosporin in Lupus Nephritis to be Presented at National Kidney Foundation 2020 Spring Clinical Meetings](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Aurinia Announces AURORA Phase 3 Clinical Data for Voclosporin in Lupus Nephritis to be Presented at National Kidney Foundation 2020 Spring Clinical Meetings
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
![NANOBIOTIX 2019 Annual Results](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
NANOBIOTIX 2019 Annual Results
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200317005789/en/
Pipeline (Graphic: NANOBIOTIX)
![Aurinia Pharmaceuticals Establishes U.S. Commercial Operations Center in Rockville, Maryland](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Aurinia Pharmaceuticals Establishes U.S. Commercial Operations Center in Rockville, Maryland
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
![Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications
![Savara Reports Fourth Quarter / Year-End 2019 Financial Results and Provides Business Update](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Savara Reports Fourth Quarter / Year-End 2019 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the fourth quarter and full year ending December 31, 2019 and provided a business update.
This
![Aurinia Launches Resource Kit for People Living With Lupus Nephritis and Partners With National Kidney Foundation on Awareness Initiative](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Aurinia Launches Resource Kit for People Living With Lupus Nephritis and Partners With National Kidney Foundation on Awareness Initiative
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) , a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and
![Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
![Transgene: Major R&D Milestones Achieved in 2019 and Strong Clinical Activity In 2020](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Transgene: Major R&D Milestones Achieved in 2019 and Strong Clinical Activity In 2020
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, publishes its financial results
![Inovio Pharmaceuticals: Berühmt-berüchtigter Shortseller attackiert!](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Inovio Pharmaceuticals: Berühmt-berüchtigter Shortseller attackiert!
Die Aktie des vergleichsweise kleinen Biotechunternehmens Inovio Pharmaceuticals (WKN: A115GK) sprang zuletzt wild hin und her. Dafür gibt es natürlich auch gute Gründe.
Zunächst schoss die Aktie